Skip to main content

Advertisement

SpringerLink
Log in

Miconazole mucoadhesive buccal tablet in high-dose therapy with autologous stem cell transplantation (HDT/ASCT)-induced mucositis

  • Original Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Oral mucositis is a major cause of morbidity in high-dose therapy/autologous stem cell transplantation (HDT/ASCT), where microbial colonization has an important pathological implication. In this study, we evaluated the impact of miconazole mucoadhesive buccal tablet (MBT) on mucositis-related complications. During two consecutive 34-month periods, patients treated with HDT/ASCT in our hematology department received either miconazole MBT (60 patients) or conventional oral amphotericin B suspensions three times a day (44 patients) in order to prevent or decrease chemotherapy-induced mucositis. The use of miconazole MBT is associated with less infectious complications as indicated by shorter antibiotic use (7.8 vs. 12.3 days; p < 0.0001), shorter intravenous antifungal use (1.4 vs. 3.6 days; p = 0.02), and a trend towards less yeast contamination in stool samples. Less patients required any analgesic drugs during hospitalization in the miconazole MBT group (18 vs. 7 %; p = 0.09). Indirect indicators of chemotherapy-induced mucositis (duration of hospitalization, morphine use) were in favor of miconazole MBT in patients with multiple myeloma (MM) but not for those with lymphoma. This study suggests that miconazole MBT provides a valid alternative to oral amphotericin B suspensions in regards to mucositis-related complications. A prospective and randomized study is warranted to establish the definite role of miconazole MBT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Grazziutti ML, Dong L, Miceli MH, Krishna SG, Kiwan E, Syed N et al (2006) Oral mucositis in patients undergoing melphalan-based autologous stem cell transplantation: incidence, risk factors and a severity predictive model. Bone Marrow Transplant 38:501–506

    Article  CAS  PubMed  Google Scholar 

  2. Vagliano L, Feraut C, Gobetto G, Trunfio A, Errico A, Campani V et al (2011) Incidence and severity of oral mucositis in patients undergoing hematopoietic SCT—results of a multicenter study. Bone Marrow Transplant 46:727–732

    Article  CAS  PubMed  Google Scholar 

  3. McCann S, Schwenkglenks M, Bacon P, Einsele H, D’Addio A, Maertens J et al (2009) The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditionning chemotherapy and autologous SCT. Bone Marrow Transplant 43:141–147

    Article  CAS  PubMed  Google Scholar 

  4. Sonis ST, Oster G, Fuchs H, Bellm L, Bradford WZ, Edelsberg J et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201–2205

    CAS  PubMed  Google Scholar 

  5. Fanning SR, Rybicki L, Kalaycio M, Andresen S, Kuczkowski E, Pohlman B et al (2006) Severe mucositis is associated with reduced survival after autologous stem cell transplantation for lymphoid malignancies. Br J Haematol 35:374–381

    Article  Google Scholar 

  6. Worthington HV, Clarkson JE, Bryan G, Furness S, Glenny AM, Littlewood A et al (2011) Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Database Syst Rev

  7. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M et al (2004) Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 1005:1995–2025

    Article  Google Scholar 

  8. Naidu MU, Ramana GV, Rani PU, Mohan IK, Suman A, Roy P (2004) Chemotherapy-induced and/or radiation therapy induced oral mucositis-complicating the treatment of cancer. Neoplasia 6:423–431

    Article  PubMed Central  PubMed  Google Scholar 

  9. Lefebvre JL, Domenge C (2002) A comparative study of the efficacy and safety of fluconazole oral suspension and amphotericin B oral suspension in cancer patients with mucositis. Oral Oncol 38:337–342

    Article  CAS  PubMed  Google Scholar 

  10. Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J et al (2009) Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant 15:1143–1238

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Robenshtok E, Gafter-Gvili A, Goldberg E, Weinberger M, Yeshurun M, Leibovici L et al (2007) Antifungal prophylaxis in cancer patients after chemotherapy or hematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol 25:5471–5489

    Article  CAS  PubMed  Google Scholar 

  12. Vazquez JA, Sobel JD (2012) Miconazole mucoadhesive tablets: a novel delivery system. Clin Infect Dis 54:1480–1484

    Article  PubMed  Google Scholar 

  13. Isham N, Ghannoum MA (2010) Antifungal activity of miconazole against recent Candida strains. Mycoses 53:434–437

    Article  CAS  PubMed  Google Scholar 

  14. Cardot JM, Chaumont C, Dubray C, Costantini D, Aiache JM (2004) Comparison of the pharmacokinetics of miconazole after administration via a bioadhesive slow release tablet and an oral gel to healthy male and female subjects. Br J Clin Pharmacol 58:345–351

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Bensadoun RJ, Daoud J, El Gueddari B, Bastit L, Gourmet R, Rosikon A et al (2008) Comparison of the efficacy and safety of miconazole 50-mg mucoadhesive buccal tablets with miconazole 500-mg gel in the treatment of oropharyngeal candidiasis: a prospective, randomized, single-blind, multicenter, comparative, phase III trial in patients treated with radiotherapy for head and neck cancer. Cancer 112:204–211

    Article  CAS  PubMed  Google Scholar 

  16. Rifkin R, Spitzer G, Orloff G, Mandanas R, McGaughey D, Zhan F et al (2010) Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-Hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 10:186–191

    Article  CAS  PubMed  Google Scholar 

  17. Gerds A, Fox-Geiman M, Dawravoo K, Rodriguez T, Toor A, Smith S et al (2010) Randomized phase III trial of pegfilgrastim versus filgrastim after autologous peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 16:678–685

    Article  CAS  PubMed  Google Scholar 

  18. Eisen D, Essell J, Broun ER, Sigmund D, DeVoe M (2003) Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy. Bone Marrow Transplant 31:51–55

    Article  CAS  PubMed  Google Scholar 

  19. Sauders DP, Epstein JB, Elad S et al (2013) Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients. Support Care Cancer 21:3191–3207

    Article  Google Scholar 

  20. Bolwell BJ, Kalaycio M, Sobecks R, Andresen S, Kuczkowski E, Bernhard L et al (2002) A multivariable analysis of factors influencing mucositis after autologous progenitor cell transplantation. Bone Marrow Transplant 30:587–591

    Article  CAS  PubMed  Google Scholar 

  21. Martino M, Montanari M, Ferrara F, Ciceri F, Scortechini I, Palmieri S, et al. Very low rate of readmission after an early discharge outpatient model for autografting in multiple myeloma patients: an Italian multicenter retrospective study. Biol Blood Marrow Transplant. doi:10.1016/j.bbmt.2014.03.027

Download references

Conflict of interest

The authors declare no conflict of interest.

Funding source

None

Author information

Authors and Affiliations

  1. Service des Maladies du Sang, CHU Angers, 4 rue Larrey, 49933, Angers Cedex 9, France

    C. Orvain, M. P. Moles-Moreau, S. François, M. Mercier, N. Ifrah, M. Hunault-Berger & A. Tanguy-Schmidt

  2. Pharmacie, CHU Angers, Angers, France

    F. Moal

  3. Centre de Recherche Clinique, CHU Angers, Angers, France

    J. F. Hamel

  4. Laboratoire d’ergonomie et d’épidémiologie en santé au travail (LEEST), Université d’Angers, Angers, France

    E. Parot-Schinkel

  5. INSERM U892, Université d’Angers, Angers, France

    N. Ifrah, M. Hunault-Berger & A. Tanguy-Schmidt

Authors
  1. C. Orvain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. P. Moles-Moreau
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S. François
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Mercier
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. F. Moal
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. J. F. Hamel
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. E. Parot-Schinkel
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. N. Ifrah
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. M. Hunault-Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. A. Tanguy-Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Tanguy-Schmidt.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Orvain, C., Moles-Moreau, M.P., François, S. et al. Miconazole mucoadhesive buccal tablet in high-dose therapy with autologous stem cell transplantation (HDT/ASCT)-induced mucositis. Support Care Cancer 23, 359–364 (2015). https://doi.org/10.1007/s00520-014-2365-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00520-014-2365-2

Keywords

Search

Navigation